Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)

NCT04440735 is registered in ClinicalTrials.gov with Kahr Medical as lead sponsor.

NCT NCT04440735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04440735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
Lead sponsor
Kahr Medical
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 7, 2020
Completion date
September 30, 2025
Enrollment
125 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, colorectal cancer, non small cell lung cancer